品牌打造缺失依托,医药营销夺路突围（Lack of brand building to rely on, pharmaceutical marketing take the road to break through）.docVIP

品牌打造缺失依托,医药营销夺路突围（Lack of brand building to rely on, pharmaceutical marketing take the road to break through） New regulatory policies trigger new marketing From EMKT. Com. Cn thinking: With the drugs manual and label management regulations and on further standardize the drug name management notice the two regulatory policies, the use of drug name to limit drug marketing into a more than one to a multi drug era, as a major issue to what drug carrier of brand marketing has been placed in front of many pharmaceutical companies. A limited commodity, brand notability The newly revised release of the drugs manual and labels management regulations requirements: the outer packing box of drugs on the smallest unit, word area commodity name shall not be greater than the generic name 1/2, and not with the generic name of company. In short, from the implementation of this regulation, consumers at one glance, the most eye-catching drug packaging will be generic drug name. At the same time, the introduction of a further standardize the drug name management notice also stressed: in addition to chemical structure, new active ingredients, and drug compounds hold patents, other varieties will not be allowed to use the commodity name. This means that in the past, through the modification of dosage forms, specifications for approval, new medicine and have the name of the situation will be improved. The original marketing problem is more than one, with compound paracetamol and amantadine hydrochloride capsules of the drug, has a different name: Hainan Asian production is called crack , Chongqing kerei production called sense of promise , called Hunan Kangpu production soon...... Different companies can make brand of products in different ways. Once the restrictions on the use of generic drugs, generic names, marketing will enter an era of multi drug because the name of the commodity restricted, even by different manufacturers, as long as the same composition of drug circulation in the m